ReviewCells2026
Rewiring Glycolysis in Cancer: From Tumor Initiation to Therapeutic Vulnerabilities.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Glycolysis is a defining feature of cancer metabolism, originally described by the Warburg effect. Increasing evidence indicates that cancer-associated glycolysis is not uniformly upregulated but dynamically rewired in response to oncogenic signaling, cellular demands, and microenvironmental cues. However, a framework integrating its temporal evolution and functional roles across tumorigenesis remains limited. In particular, how glycolytic rewiring drives malignant transformation, adapts during tumor progression, and generates context-dependent vulnerabilities has not been systematically synthesized. In this review, we examine glycolysis as a dynamic metabolic network evolving throughout tumor development. We discuss how early glycolytic rewiring, driven by oncogenic signaling and metabolic-epigenetic coupling, supports cell fate transitions and establishes redox and biosynthetic capacity during tumorigenesis. We then outline how glycolysis is remodeled during tumor progression through coordinated transcriptional, epigenetic, and post-translational regulation, as well as microenvironmental interactions and metabolic heterogeneity. Furthermore, we highlight glycolysis as an integrative hub linking immune evasion, cell death regulation, and metabolic plasticity, and discuss how glycolytic rewiring creates context-dependent metabolic dependencies that may be therapeutically exploited, along with emerging technologies that enable high-resolution characterization of tumor metabolism. Together, this review provides a conceptual framework for understanding glycolytic rewiring in cancer and outlines potential avenues for targeting metabolic vulnerabilities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.